AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $245.10 billion. The enterprise value is $273.03 billion.
| Market Cap | 245.10B |
| Enterprise Value | 273.03B |
Important Dates
The last earnings date was Monday, July 27, 2026, before market open.
| Earnings Date | Jul 27, 2026 |
| Ex-Dividend Date | Aug 7, 2026 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 74.53% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 23.46 and the forward PE ratio is 14.59.
| PE Ratio | 23.46 |
| Forward PE | 14.59 |
| PS Ratio | 3.99 |
| Forward PS | 3.76 |
| PB Ratio | 4.87 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.98 |
| P/OCF Ratio | 17.89 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.43, with an EV/FCF ratio of 25.59.
| EV / Earnings | 26.14 |
| EV / Sales | 4.45 |
| EV / EBITDA | 13.43 |
| EV / EBIT | 19.54 |
| EV / FCF | 25.59 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 0.64.
| Current Ratio | 0.89 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 1.59 |
| Debt / FCF | 3.03 |
| Interest Coverage | 9.92 |
Financial Efficiency
Return on equity (ROE) is 21.96% and return on invested capital (ROIC) is 16.05%.
| Return on Equity (ROE) | 21.96% |
| Return on Assets (ROA) | 8.02% |
| Return on Invested Capital (ROIC) | 16.05% |
| Return on Capital Employed (ROCE) | 16.58% |
| Weighted Average Cost of Capital (WACC) | 5.20% |
| Revenue Per Employee | $645,279 |
| Profits Per Employee | $109,842 |
| Employee Count | 95,100 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.68 |
Taxes
In the past 12 months, AstraZeneca has paid $2.13 billion in taxes.
| Income Tax | 2.13B |
| Effective Tax Rate | 16.95% |
Stock Price Statistics
The stock price has increased by +1.05% in the last 52 weeks. The beta is 0.21, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +1.05% |
| 50-Day Moving Average | 174.13 |
| 200-Day Moving Average | 183.84 |
| Relative Strength Index (RSI) | 33.98 |
| Average Volume (20 Days) | 3,958,449 |
Short Selling Information
The latest short interest is 1.84 million, so 0.12% of the outstanding shares have been sold short.
| Short Interest | 1.84M |
| Short Previous Month | 1.53M |
| Short % of Shares Out | 0.12% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 0.65 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $61.37 billion and earned $10.45 billion in profits. Earnings per share was $6.68.
| Revenue | 61.37B |
| Gross Profit | 50.13B |
| Operating Income | 14.64B |
| Pretax Income | 12.59B |
| Net Income | 10.45B |
| EBITDA | 20.33B |
| EBIT | 13.97B |
| Earnings Per Share (EPS) | $6.68 |
Balance Sheet
The company has $4.97 billion in cash and $32.35 billion in debt, with a net cash position of -$27.38 billion or -$17.65 per share.
| Cash & Cash Equivalents | 4.97B |
| Total Debt | 32.35B |
| Net Cash | -27.38B |
| Net Cash Per Share | -$17.65 |
| Equity (Book Value) | 50.37B |
| Book Value Per Share | 32.43 |
| Working Capital | -3.59B |
Cash Flow
In the last 12 months, operating cash flow was $13.70 billion and capital expenditures -$3.03 billion, giving a free cash flow of $10.67 billion.
| Operating Cash Flow | 13.70B |
| Capital Expenditures | -3.03B |
| Depreciation & Amortization | 5.27B |
| Net Borrowing | -1.89B |
| Free Cash Flow | 10.67B |
| FCF Per Share | $6.88 |
Margins
Gross margin is 81.69%, with operating and profit margins of 23.86% and 17.02%.
| Gross Margin | 81.69% |
| Operating Margin | 23.86% |
| Pretax Margin | 20.51% |
| Profit Margin | 17.02% |
| EBITDA Margin | 33.12% |
| EBIT Margin | 22.77% |
| FCF Margin | 17.38% |
Dividends & Yields
This stock pays an annual dividend of $3.23, which amounts to a dividend yield of 2.07%.
| Dividend Per Share | $3.23 |
| Dividend Yield | 2.07% |
| Dividend Growth (YoY) | 3.19% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 48.35% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 2.11% |
| Earnings Yield | 4.26% |
| FCF Yield | 4.35% |
Analyst Forecast
The average price target for AstraZeneca is $213.69, which is 36.89% higher than the current price. The consensus rating is "Buy".
| Price Target | $213.69 |
| Price Target Difference | 36.89% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 6.67% |
| EPS Growth Forecast (3Y) | 11.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.57 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.57 |
| Piotroski F-Score | 7 |